venture capital-backed Brandon BioCatalyst's CUREator is set to deliver a BioMedTech Incubator (BMTI) to address dementia after recieving a $50 million grant from the Federal Government.
The company, in partnership with ANDHealth, will focus on developing research discoveries and medical innovations with commercial potential to improve the lives of Australians suffering from cognitive decline.
The program will be delivered over the next five years in collaboration with Dementia Australia, which will lead a community advisory board comprising people impacted by dementia to guide the development of new technologies and treatments.
"Dementia Australia is pleased to be actively involved with the program's delivery along with Brandon BioCatalyst and ANDHealth," said Dr Kaele Stokes, the peak body's Executive Director of Services, Advocacy and Research.
"We are committed to supporting the delivery of this important program by ensuring the voice of the consumers - both those living with dementia and their families and carers - are prioritised throughout this program and providing dementia-specific expertise for the incubator."
According to Dementia Australia, there will be 812,500 people living with dementia by 2054, which highlights the necessity of programs like BMTI to proactively address the rising health issue.
The program will prepare participants to be 'investor-ready' on completion. JG
The above article was sent to subscribers in Pharmacy Daily's issue from 01 Mar 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Mar 24
